The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S3-S11 , April 2006

Preventing Osteoporosis-Related Fractures: An Overview

  • Margery Gass, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    • Corresponding Author InformationAddress correspondence to Margery Gass, MD, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, Ohio 45267-0526.
    • ,
  • Bess Dawson-Hughes, MD

      Affiliations

    • Division of Endocrinology, Tufts University School of Medicine, Boston, Massachusetts, USA

References 

  1. NIH Consensus Panel on Osteoporosis Prevention, Diagnosis, and Therapy . Osteoporosis prevention, diagnosis, and therapy . JAMA . 2001;285:785–795
  2. US Department of Health and Human Services . Bone Health and Osteoporosis (A Report of the Surgeon General) . Rockville, MD: US Dept of Health and Human Services, Public Health Service, Office of the Surgeon General; 2004;
  3. National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Available at: http://www.nof.org/_vti_bin/shtml.dll/physguide/index.htm. Accessed April 27, 2005.
  4. Empana JP , Dargent-Molina P , Breart G  EPIDOS Group . Effect of hip fracture on mortality in elderly women (the EPIDOS prospective study) . J Am Geriatr Soc . 2004;52:685–690
  5. Ensrud KE , Thompson DE , Cauley JA , et al.  Fracture Intervention Trial Research Group   Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass . J Am Geriatr Soc . 2000;48:241–249
  6. Kado DM , Browner WS , Palermo L , Nevitt MC , Genant HK , Cummings SR  Study of Osteoporotic Fractures Research Group . Vertebral fractures and mortality in older women (a prospective study) . Arch Intern Med . 1999;159:1215–1220
  7. Nevitt MC , Ettinger B , Black DM , et al.   The association of radiographically detected vertebral fractures with back pain and function (a prospective study) . Ann Intern Med . 1998;128:793–800
  8. Jarvinen TL , Kannus P , Sievanen H . Estrogen and bone—a reproductive and locomotive perspective . J Bone Miner Res . 2003;1:1921–1931
  9. Kanis JA . Diagnosis of osteoporosis and assessment of fracture risk . Lancet . 2002;359:1929–1936
  10. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland: World Health Organization, 1994. WHO Technical Report Series 843.
  11. North American Menopause Society . Management of postmenopausal osteoporosis position statement of the North American Menopause Society . Menopause . 2002;9:84–101
  12. Hodgson SF , Watts NB , Bilezikian JP , et al.  AACE Osteoporosis Task Force   American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis (2001 edition, with selected updates for 2003) . Endocr Pract . 2003;9:544–564
  13. Going S , Lohman T , Houtkooper L , et al.   Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy . Osteoporos Int . 2003;14:637–643
  14. Fiatarone MA , Marks EC , Ryan ND , Meredith CN , Lipsitz LA , Evans WJ . High-intensity strength training in nonagenarians (effects on skeletal muscle) . JAMA . 1990;263:3029–3034
  15. Dawson-Hughes B , Harris SS , Krall EA , Dallal GE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older . N Engl J Med . 1997;337:670–676
  16. Dawson-Hughes B , Dallal GE , Krall EA , et al.   A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women . N Engl J Med . 1990;323:878–883
  17. Reid IR , Ames RW , Evans MC , Gamble GD , Sharpe SJ . Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women (a randomized controlled trial) . Am J Med . 1995;98:331–335
  18. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet. Available at: http://ods.od.nih.gov/factsheets/calcium.asp. Accessed March 1, 2006.
  19. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet: Vitamin D. Available at: http://ods.od.nih.gov/factsheets/vitamind.asp. Accessed March 1, 2006.
  20. O’Loughlin JL , Robitaille Y , Boivin JF , Suissa S . Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly . Am J Epidemiol . 1993;137:342–354
  21. National Osteoporosis Foundation. Patient Info: Fall Prevention. Available at http://www.nof.org/patientinfo/fall_prevention.htm. Accessed April 27, 2005.
  22. Parker MJ , Gillespie LD , Gillespie WJ . Hip protectors for preventing hip fractures in the elderly . Cochrane Database Syst Rev . 2004;3: CD001255
  23. Adachi K , Chole RA . Inhibition of osteoclast recruitment at a local site by 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) . Ann Otol Rhinol Laryngol . 1990;99(pt 1):738–741
  24. Carano A , Teitelbaum SL , Konsek JD , Schlesinger PH , Blair HC . Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro . J Clin Invest . 1990;85:456–461
  25. Hughes DE , Wright KR , Uy HL , et al.   Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo . J Bone Miner Res . 1995;10:1478–1487
  26. Harris ST , Watts NB , Genant HK , et al.  Vertebral Efficacy With Risedronate Therapy (VERT) Study Group   Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis (a randomized controlled trial) . JAMA . 1999;282:1344–1352
  27. Fosamax (alendronate sodium) tablet and oral solution [prescribing information] . Whitehouse Station, NJ: Merck & Co., Inc; 2004;
  28. Black DM , Cummings SR , Karpf DB , et al.  Fracture Intervention Trial Research Group   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures . Lancet . 1996;348:1535–1541
  29. Cummings SR , Black DM , Thompson DE , et al.   Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures (results from the Fracture Intervention Trial) . JAMA . 1998;280:2077–2082
  30. Actonel (risedronate sodium tablets) [prescribing information] . Kansas City, MO: Aventis Pharmaceuticals Inc; 2004;
  31. Boniva (ibandronate sodium) tablets [prescribing information] . Nutley, NJ: Roche Laboratories Inc; 2005;
  32. Ruggiero SL , Mehrotra B , Rosenberg TJ , Engroff SL . Osteonecrosis of the jaws associated with the use of bisphosphonates (a review of 63 cases) . J Oral Maxillofac Surg . 2004;62:527–534
  33. Delaney MF , Hurwitz S , Shaw J , LeBoff MS . Bone density changes with once weekly risedronate in postmenopausal women . J Clin Densitom . 2003;6:45–50
  34. Emkey R . Alendronate and risedronate for the treatment of postmenopausal osteoporosis (clinical profiles of the once-weekly and once-daily dosing formulations) . MedGenMed . 2004;6:6; [serial online]
  35. Gordon MS , Gordon MB . Response of bone mineral density to once-weekly administration of risedronate . Endocr Pract . 2002;8:202–207
  36. Rizzoli R , Greenspan SL , Bone G , et al.   Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis . J Bone Miner Res . 2002;17:1988–1996
  37. Cramer JA , Amonkar MM , Hebborn A , Suppapanya N . Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? . Abstract M434 J Bone Miner Res . 2004;19(suppl 1):S448
  38. Delmas PD . Treatment of postmenopausal osteoporosis . Lancet . 2002;359:2018–2026
  39. Ettinger B , Black DM , Mitlak BH , et al.  Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators   Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene (results from a 3-year randomized clinical trial) . JAMA . 1999;282:637–645
  40. Cummings SR , Eckert S , Krueger KA , et al.   The effect of raloxifene on risk of breast cancer in postmenopausal women (results from the MORE [Multiple Outcomes of Raloxifene Evaluation] randomized trial) . JAMA . 1999;281:2189–2197
  41. Cauley JA , Norton L , Lippman ME , et al.   Continued breast cancer risk reduction in postmenopausal women treated with raloxifene (4-year results from the MORE [Multiple Outcomes of Raloxifene Evaluation] trial) . Breast Cancer Res Treat . 2001;65:125–134
  42. Rossouw JE , Anderson GL , Prentice RL , et al.  Writing Group for the Women’s Health Initiative Investigators   Risks and benefits of estrogen plus progestin in healthy postmenopausal women (principal results from the Women’s Health Initiative randomized controlled trial) . JAMA . 2002;288:321–333
  43. Cauley JA , Robbins J , Chen Z , et al.  Women’s Health Initiative Investigators   Effects of estrogen plus progestin on risk of fracture and bone mineral density (the Women’s Health Initiative randomized trial) . JAMA . 2003;290:1729–1738
  44. Forteo (teriparatide rDNA origin) injection 750 μg/3 mL [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2004.
  45. Neer RM , Arnaud CD , Zanchetta JR , et al.   Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis . N Engl J Med . 2001;344:1434–1441
  46. Miacalcin (calcitonin-salmon) nasal spray [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2003.
  47. Chesnut CH , Silverman S , Andriano K , et al.  PROOF Study Group   A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis (the Prevent Recurrence of Osteoporotic Fractures Study) . Am J Med . 2000;109:267–276
  48. Cranney A , Tugwell P , Zytaruk N , et al.  Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group   Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis . Endocr Rev . 2002;23:540–551

PII: S0002-9343(05)01197-6

doi: 10.1016/j.amjmed.2005.12.017

The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S3-S11 , April 2006

Article Tools

* Image Usage & Resolution